Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Flt3 receptor tyrosine kinase as a drug target in leukemia.

Current pharmaceutical design - 1 Jan 2004

Schmidt-Arras Dirk, Schwäble Joachim, Böhmer Frank-D, Serve Hubert

Abstract excerpt

The hematopoietic class III receptor tyrosine kinase (RTK) Flt3 (Flk2, STK1) has recently received much attention as a potential drug target. Activation of Flt3 by different types of mutations plays an important role for proliferation, resistance to apoptosis, and prevention of differentiation of leukemic blasts in acute myeloid leukemia (AML). At least one type of such mutations - an internal tandem duplication...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Delivery Systems
Share to Enzyme Inhibitors
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia

Share to Mutation

Share to Proto-Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 15180525
DOI: 10.2174/1381612043384394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Flt3 receptor tyrosine kinase as a drug target in leukemia.PMID 15180525Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

Targeting FLT3 to treat leukemia.Semantic proximity Read ↗

Novel FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

Investigational drugs targeting FLT3 for leukemia.Semantic proximity Read ↗

FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia.Semantic proximity Read ↗

Targeting FLT3 for the treatment of leukemia.Semantic proximity Read ↗

FLT3 Inhibitors for Treating Acute Myeloid Leukemia.Semantic proximity Read ↗

N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants.Semantic proximity Read ↗

FLT3 inhibition as a targeted therapy for acute myeloid leukemia.Semantic proximity Read ↗

The role of FLT3 kinase as an AML therapy target.Semantic proximity Read ↗

FLT3 mutations: biology and treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.